Min Kyeong Jang

Min Kyeong Jang

Auto-generated profile, based on publicly available information

Min Kyeong Jang

Mo-Im Kim Nursing Research Institute, Yonsei University College of Nursing, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in Journal of Clinical Nursing
Verified
Journal Article
Open access
PDF file
SKSue Kim
Sue Kim
JHJeehee Han
Jeehee Han
MLMin Young Lee
Min Young Lee
MJMin Kyeong Jang
Min Kyeong Jang
Aims and objectives: To identify the experience of breast cancer survivors regarding cancer‐related fatigue, exercise and exercise adherence.Background: Cancer‐related fatigue is a common symptom among cancer survivors that limits quality of life. Despite exercise being recommended as a viable solution to manage cancer‐related fatigue, relatively few research studies on the experience of cancer‐related fatigue and exercise adherence have been conducted.Design: This was a qualitative study to identify breast cancer survivors’ experience of cancer‐related fatigue, exercise and exercise adherence. This paper adhered to the COREQ checklist in reporting.Methods: Four focus group interviews were conducted with 16 breast cancer survivors who had fatigue score of 4 out of 10 (moderate fatigue) or greater. Ethical approval was obtained and participants met for focus group interview discussion. The interview guide included questions on cancer‐related fatigue, barriers and facilitators of exercising, strategies for exercise adherence and suggestions for a supportive programme.Results: Four themes were identified through thematic analysis: (a) The insidious and overpowering nature of cancer‐related fatigue; (b) exercising when experiencing fatigue surrounded by prevailing myths; (c) multiple barriers to exercise; and (d) facilitative factors to continue exercising despite fatigue.Conclusions: Participants’ experience of moderate or greater cancer‐related fatigue prevented them from exercising, despite knowing its importance, and limited them to passive activities. Misconceptions that exercise is associated with lymphedema and risk of recurrence, poor psychosocial self‐image and lack of clear knowledge and exercise programmes for cancer survivors further limited adherence to exercise. In contrast, finding comfort and strength through exercising and interacting with other breast cancer survivors were facilitative factors.Relevance to clinical practice: The insights shared by breast cancer survivors experiencing cancer‐related fatigue can contribute to developing an exercise adherence programme as a way to manage and alleviate fatigue and establish healthy survivorship care.

4 May 2020 in Anticancer Research
Verified
Journal Article
Open access
PDF file
MJMin Kyeong Jang
Min Kyeong Jang
CPChang Park
Chang Park
SHSusan Hong
Susan Hong
HLHongjin Li
Hongjin Li
EREsther Rhee
Esther Rhee
ADArdith Z. Doorenbos
Ardith Z. Doorenbos
Background/Aim: Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors. Materials and Methods: We searched primary original research published through October 2019 in four databases: MEDLINE via PubMed, Scopus, CINAHL, and Embase. Results: Fifteen studies were included, 60% published in the past 2 years (2018-2019). Advanced non-small cell lung cancer was the most frequently reported cancer, and overall survival the most often identified key related factor. Mean difference in skeletal muscle index during chemotherapy was 2.72 (95%CI=1.77-3.67, p=0.00), with muscle loss in males (4.52, 95%CI=3.34-5.71, p=0.00) about 1.6 times higher than that in females (2.86, 95%CI=0.81-4.92, p=0.01). Conclusion: Oncologists should recognize sex-specific differences in skeletal muscle mass loss during chemotherapy and consider adjusting treatment accordingly.

28 May 2021 in Cancer Nursing
Verified
Journal Article
Open access
MJMin Kyeong PhD Jang
Min Kyeong PhD Jang
CPChang Park
Chang Park
LTLisa Tussing-Humphreys
Lisa Tussing-Humphreys
BFBo Fernhall
Bo Fernhall
SPShane A Phillips
Shane A Phillips
ADArdith Z. Doorenbos
Ardith Z. Doorenbos
Background: Among people with cancer undergoing chemotherapy, generalized loss of muscle mass, termed secondary sarcopenia, is associated with treatment toxicities and physical disability. Objective: This systematic review and meta-analysis aimed to provide an overview of current interventions for sarcopenia in cancer patients receiving chemotherapy and to assess potentially effective interventions. Methods: We searched PubMed, Scopus, CINAHL (Cumulative Index to Nursing and Allied Health Literature) Plus, and EMBASE for primary original research of exercise and nutrition interventions for sarcopenia published in English. The review used PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines. Standardized mean difference and 95% confidence interval (CI) were calculated as effect measures by applying the random-effects model. Results: The 6 included studies showed a trend toward significantly increasing skeletal muscle mass after intervention (mean difference, 0.168; 95% CI, −0.015 to 0.352; P = .072), with no significant changes in lean body mass loss after intervention (mean difference, −0.014; 95% CI, −1.291 to 1.264; P = .983). Resistance exercise and combined exercise and nutrition intervention were more effective at preserving or increasing muscle mass. Conclusions: Early implementation of a resistance exercise intervention or a combined exercise and nutrition intervention is a promising strategy for avoiding muscle mass loss during chemotherapy. Additional evidence-based assessments of interventions for secondary sarcopenia are needed to identify the most effective approach. Implications for Practice: In clinical practice, oncology nurses should frequently assess cancer patients’ muscle mass and when warranted should implement the most feasible early sarcopenia intervention to minimize the adverse outcomes of this condition.

26 August 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
MJMin Kyeong Jang
Min Kyeong Jang
SPSeho Park
Seho Park
CPChang Park
Chang Park
ADArdith Z. Doorenbos
Ardith Z. Doorenbos
JGJieon Go
Jieon Go
SKSue Kim
Sue Kim
Background: Sarcopenia is receiving attention in oncology as a predictor of increased chemotherapy toxicities. Research into body composition change during neoadjuvant chemotherapy for breast cancer is both urgently needed and generally lacking. This study assessed sarcopenia prevalence before and after neoadjuvant chemotherapy using CT imaging, evaluated body composition changes during neoadjuvant chemotherapy, and determined predictors of sarcopenia status after neoadjuvant chemotherapy for breast cancer.Materials and Methods: In this retrospective, descriptive study, we used data collected from 2017 to 2020 to measure body composition parameters on cross-sectional CT slices for 317 Korean women with breast cancer patients before and at completion of neoadjuvant chemotherapy. Changes in skeletal muscle index, visceral fat index, subcutaneous fat index, and sarcopenia were assessed and correlated, and multivariate logistic regression was conducted to identify predictive factors associated with sarcopenia status at completion of neoadjuvant chemotherapy.Results: Of the 80 breast cancer patients (25.2%) who had sarcopenia before beginning neoadjuvant chemotherapy, 64 (80.0%) retained their sarcopenia status after chemotherapy. Weight, body mass index, body surface area, and visceral fat index showed significant increases after neoadjuvant chemotherapy; notably, only skeletal muscle index significantly decreased, showing a reduction of 0.44 cm2/m2 (t (316) = 2.15, p <.5). Lower skeletal muscle index at baseline was associated with greater loss of muscle mass during neoadjuvant chemotherapy (r = −.24, p <.001). Multivariate logistic regression showed that baseline sarcopenia status was the only significant predictor of sarcopenia status after neoadjuvant chemotherapy (p <.001). Specifically, the log odds of sarcopenia after neoadjuvant chemotherapy were 3.357 higher in the baseline sarcopenia group than in the group without baseline sarcopenia (β = 3.357, p <.001).Conclusion: Sarcopenia during neoadjuvant chemotherapy can be obscured by an increasing proportion of fat in body composition if clinical assessment focuses on only body mass index or body surface area rather than muscle mass. For breast cancer patients who have sarcopenia when they begin neoadjuvant chemotherapy, the risk of muscle mass loss during treatment is alarmingly high. To reduce masking of muscle mass loss during treatment, comprehensive evaluation of body composition, beyond body surface area assessment, is clearly needed.

11 March 2022 in Death Studies
Verified
Journal Article
Closed access
SPSungwon Park
Sungwon Park
HKHyungkyung Kim
Hyungkyung Kim
MJMin Kyeong Jang
Min Kyeong Jang
HKHyungsub Kim
Hyungsub Kim
RRRebecca Raszewski
Rebecca Raszewski
ADArdith Z. Doorenbos
Ardith Z. Doorenbos
The COVID-19 pandemic revealed a need for people and communities for death preparation. Few studies have examined community-level interventions for death preparation and education. This scoping review scrutinized the relevant literature following PRISMA 2018 guidelines. Six databases were searched for articles published between 2010 and 2020. We found that cultural, socioeconomic, and individual values affected death preparation and that online courses and life-death education were effective preparation methods. Additional research is needed to identify the population-specific effectiveness of interventions. To fully investigate death preparation and education at the community level, theory-based studies employing quantitative and qualitative methods are also needed.

3 May 2024 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
MJMin Kyeong Jang
Min Kyeong Jang
SPSungwon Park
Sungwon Park
RRRebecca Raszewski
Rebecca Raszewski
CPChang Gi Park
Chang Gi Park
ADArdith Z. Doorenbos
Ardith Z. Doorenbos
SKSue Kim
Sue Kim